secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2026-08-13T11:00:19+00:00
Accession:  0001104659-26-095424
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC wins bankruptcy auction for Sangamo's Fabry gene therapy ST-920; $111M upfront
--------------------------------------------------------------------------------

- Deal: $111M upfront plus up to $100M milestones ($80M on accelerated approval, $20M on traditional FDA approval).
- ST-920 is a one-time AAV gene therapy; BLA submission for accelerated approval expected Q4 2026.
- Phase 1/2 STAAR data showed positive eGFR slope at 52 weeks; durability up to 4.5 years in earliest patient.
- Close expected late Q3/early Q4 2026, subject to bankruptcy court approval, antitrust review, and customary conditions.
- PTC expects no impact on 2026 cash flow break-even; leverages existing rare disease commercial infrastructure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000110465926095424/0001104659-26-095424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000110465926095424/tmb-20260812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-095424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer